Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)

Kyaw Zin Thein; Sarina A. Piha-Paul; Apostolia Tsimberidou; Daniel D. Karp; Filip Janku; Abdulrazzak Zarifa; Jatin Shah; Denái R. Milton; Stacie Bean; Lacey McQuinn; Jing Gong; Rivka Colen; Brett W. Carter; Vivek Subbiah; Deby C. Ogbonna; Shubham Pant; Funda Meric-Bernstam; Aung Naing

doi:10.1007/s10637-021-01192-5

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)

Kyaw Zin Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Abdulrazzak Zarifa, Jatin Shah, Denái R. Milton, Stacie Bean, Lacey McQuinn, Jing Gong, Rivka Colen, Brett W. Carter, Vivek Subbiah, Deby C. Ogbonna, Shubham Pant, Funda Meric-Bernstam, Aung Naing

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The article Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study was originally published electronically on the publisher’s internet portal on 28 April 2021 without open access. After publication in volume [39], issue [5], pages [1357–1365] the author decided to opt for Open Choice and to make the article an Open Access publication.

Original language	English (US)
Pages (from-to)	461
Number of pages	1
Journal	Investigational New Drugs
Volume	40
Issue number	2
DOIs	https://doi.org/10.1007/s10637-021-01192-5
State	Published - Apr 2022

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/s10637-021-01192-5

Fingerprint

Dive into the research topics of 'Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)'. Together they form a unique fingerprint.

Cite this

Thein, K. Z., Piha-Paul, S. A., Tsimberidou, A., Karp, D. D., Janku, F., Zarifa, A., Shah, J., Milton, D. R., Bean, S., McQuinn, L., Gong, J., Colen, R., Carter, B. W., Subbiah, V., Ogbonna, D. C., Pant, S., Meric-Bernstam, F., & Naing, A. (2022). Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0). Investigational New Drugs, 40(2), 461. https://doi.org/10.1007/s10637-021-01192-5

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0). / Thein, Kyaw Zin; Piha-Paul, Sarina A.; Tsimberidou, Apostolia et al.
In: Investigational New Drugs, Vol. 40, No. 2, 04.2022, p. 461.

Research output: Contribution to journal › Comment/debate › peer-review

Thein, KZ, Piha-Paul, SA, Tsimberidou, A, Karp, DD, Janku, F, Zarifa, A, Shah, J, Milton, DR, Bean, S, McQuinn, L, Gong, J, Colen, R, Carter, BW, Subbiah, V, Ogbonna, DC, Pant, S, Meric-Bernstam, F & Naing, A 2022, 'Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)', Investigational New Drugs, vol. 40, no. 2, pp. 461. https://doi.org/10.1007/s10637-021-01192-5

Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A et al. Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0). Investigational New Drugs. 2022 Apr;40(2):461. doi: 10.1007/s10637-021-01192-5

Thein, Kyaw Zin ; Piha-Paul, Sarina A. ; Tsimberidou, Apostolia et al. / Correction to : Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0). In: Investigational New Drugs. 2022 ; Vol. 40, No. 2. pp. 461.

@article{a28a92ef9eec4d96b218c60126d00168,

title = "Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)",

abstract = "The article Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study was originally published electronically on the publisher{\textquoteright}s internet portal on 28 April 2021 without open access. After publication in volume [39], issue [5], pages [1357–1365] the author decided to opt for Open Choice and to make the article an Open Access publication.",

author = "Thein, {Kyaw Zin} and Piha-Paul, {Sarina A.} and Apostolia Tsimberidou and Karp, {Daniel D.} and Filip Janku and Abdulrazzak Zarifa and Jatin Shah and Milton, {Den{\'a}i R.} and Stacie Bean and Lacey McQuinn and Jing Gong and Rivka Colen and Carter, {Brett W.} and Vivek Subbiah and Ogbonna, {Deby C.} and Shubham Pant and Funda Meric-Bernstam and Aung Naing",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2021.",

year = "2022",

month = apr,

doi = "10.1007/s10637-021-01192-5",

language = "English (US)",

volume = "40",

pages = "461",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Correction to

T2 - Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)

AU - Thein, Kyaw Zin

AU - Piha-Paul, Sarina A.

AU - Tsimberidou, Apostolia

AU - Karp, Daniel D.

AU - Janku, Filip

AU - Zarifa, Abdulrazzak

AU - Shah, Jatin

AU - Milton, Denái R.

AU - Bean, Stacie

AU - McQuinn, Lacey

AU - Gong, Jing

AU - Colen, Rivka

AU - Carter, Brett W.

AU - Subbiah, Vivek

AU - Ogbonna, Deby C.

AU - Pant, Shubham

AU - Meric-Bernstam, Funda

AU - Naing, Aung

PY - 2022/4

Y1 - 2022/4

N2 - The article Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study was originally published electronically on the publisher’s internet portal on 28 April 2021 without open access. After publication in volume [39], issue [5], pages [1357–1365] the author decided to opt for Open Choice and to make the article an Open Access publication.

AB - The article Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study was originally published electronically on the publisher’s internet portal on 28 April 2021 without open access. After publication in volume [39], issue [5], pages [1357–1365] the author decided to opt for Open Choice and to make the article an Open Access publication.

UR - http://www.scopus.com/inward/record.url?scp=85117942602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117942602&partnerID=8YFLogxK

U2 - 10.1007/s10637-021-01192-5

DO - 10.1007/s10637-021-01192-5

M3 - Comment/debate

C2 - 34705134

AN - SCOPUS:85117942602

SN - 0167-6997

VL - 40

SP - 461

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this